NHS delays drive growing number of patients to private healthcare

The share of people using private healthcare in England rose from 9% in 2023 to 16% in 2025, driven primarily by long NHS waiting times and a desire for greater convenience. Healthwatch England warns this trend is creating a growing 'two-tier' system even as NHS data show the overall waiting list fell to 7.25 million treatments by end-January (third consecutive monthly decline). Higher earners are disproportionately using private care, and campaigners and providers are calling for faster action on waiting lists and improved patient communication.

Analysis

Private providers, diagnostics firms and outpatient-capex owners stand to capture disproportionate margin expansion because elective flows are more profitable per case than walk-in NHS work; a persistent diversion of even a few percent of elective volume can translate to mid-single-digit topline tailwinds for focused operators and 200–400bp EBITDA expansion absent aggressive reinvestment. Staffing is the choke point: private chains will compete on pay and scheduling, which compresses near-term margins and forces incremental capex for modular day-surgery capacity, favoring balance-sheet-rich players that can deploy beds quickly.

Policy and political reaction are the dominant catalysts and tail risks over the 3–24 month horizon. A targeted government programme that routes incremental funding into NHS capacity or caps private sector pricing would blunt private revenue growth within quarters, while a multi-year shift in employer-sponsored health benefits or tax incentives could lock in higher private penetration and justify elevated valuations for acquirers.

Second-order winners include healthcare REITs that own outpatient clinics and specialised imaging/implant vendors whose revenue is per-procedure and scales with elective throughput; second-order losers are NHS-dependent service contractors and regional hospitals that lose high-margin cases and face deteriorating payer mix. Expect an acceleration of M&A as private operators seek bolt-on surgical centers to avoid build-time constraints — that creates arbitrage opportunities for strategic buyers but raises execution risk for over-levered acquirers.

Key Decisions for Investors

• Long SPI.L (Spire Healthcare) via 6–12 month call options sized 1–2% portfolio: asymmetric upside if private elective volumes continue to reprice higher; downside limited to premium (risk). Hedge by selling a portion if share rallies >30% (reward).
• Buy PHP.L (Primary Health Properties) stock, 12–24 month horizon, 3–5% position: stable dividend + reversionary yield optionality as private operators expand leases. Key risk: UK real estate yields rising; set stop at -20% or hedge duration exposure with short gilt futures.
• Long RHC.AX (Ramsay Health Care) 9–18 months, small position for geographic diversification: benefits from consolidation and cross-border patient flows. Tail risk: currency and integration; cap position at 2% and trim on >25% gain.
• Pair trade for event risk management: long SPI.L / short a UK NHS services outsourcer (idiosyncratic selection) or alternatively short a domestic staffing agency with high NHS exposure — horizon 6–12 months to isolate shift in payer mix. This reduces market beta while expressing privatization spread; monitor political headlines closely and tighten stops on policy interventions.